NCM · Drug Manufacturers - Specialty & Generic

SCYX (SCYX) Stock

$3.57 -4.29% NCM: SCYX Healthcare

Valuation

MetricValue
Price$3.57
Market Cap$22.45M
P/E Ratio-3.94
P/B Ratio0.69
P/S Ratio1.65
EPS (TTM)$-0.17
52-Week High$10.48
52-Week Low$3.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.37%
ROA-15.25%
ROCE-32.65%
Gross Margin-76.19%
Operating Margin-76.19%
Net Margin-1.21%
Debt/Equity0.05
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$13.0M$5.0M$140.0M$4.0M$21.0M
Operating Profit$-61.0M$-86.0M$73.0M$-37.0M$-16.0M
Net Profit$-33.0M$-63.0M$67.0M$-21.0M$-9.0M
EPS$-1.25$-1.47$1.39$-0.44$-0.17
Op Margin-462.2%-1684.5%51.9%-990.8%-78.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$120.0M$88.0M$128.0M$91.0M$59.0M
Total Liabilities$79.0M$85.0M$55.0M$36.0M$10.0M
Cash$104.0M$46.0M$34.0M$16.0M$21.0M
Borrowings$44.0M$49.0M$15.0M$16.0M$2.0M

Latest News

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) GlobeNewswire · Jun 30, 2026 Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested TipRanks · Jun 1, 2026 SCYNEXIS Announces One-for-Eight Reverse Stock Split GlobeNewswire · May 22, 2026 Scynexis: Q1 Earnings Snapshot Associated Press · May 11, 2026 SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-55.0M$-80.0M$60.0M$-24.0M$-5.0M
Investing Cash Flow$-2.0M$-27.0M$-35.0M$6.0M$24.0M
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$11.0M$-59.0M$-11.0M$-18.0M$5.0M
Free Cash Flow$-56.0M$-80.0M$60.0M$-24.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-17.60%
Quick Ratio3.94
Interest Coverage—
Return 1Y-21.96%
Return 3Y-78.43%
Return 5Y-91.16%

Ownership

Insiders Held2.00%
Institutions Held49.42%
Institutions Float Held50.43%
Institutional HolderSharesReport Date
Squadron Capital Management LLC951,0872026-03-31
Great Point Partners LLC944,2932026-03-31
Heights Capital Management, Inc 260,8702026-03-31
Avidity Partners Management, LP260,2082026-03-31
Kingdon Capital Management LLC247,8112026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
COSM $0.21 +3.75% -0.44 $12.88M 0.00%
CVKD $2.06 +0.98% -0.78 $6.38M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
NRSNNeuroSense Therapeutics Ltd. $0.60 -0.35% -1.35 $21.21M 0.00%

About SCYX

SCYX is led by CEO David Gonzalez Angulo, employs 28 people, headquartered in US, publicly traded since 2014.

SCYX stock trades at $3.57 with a market capitalization of $22.45M. The stock is valued at a price-to-earnings (P/E) ratio of -3.94, price-to-book of 0.69, price-to-sales of 1.65. Over the past 52 weeks the stock has ranged between $3.57 and $10.48, and currently trades 65.9% below its 52-week high.

On profitability, SCYX generates a return on equity (ROE) of -18.37%, return on capital employed of -32.65%, an operating margin of -76.19%, a net profit margin of -1.21%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides